GT Biopharma Inc. Common Stock earnings per share and revenue
On Nov 14, 2025, GTBP reported earnings of -0.79 USD per share (EPS) for Q3 25, missing the estimate of -0.38 USD, resulting in a -103.82% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -25.34% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.22 USD, with revenue projected to reach -- USD, implying an decrease of -72.15% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
What were GT Biopharma Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, GT Biopharma Inc. Common Stock reported EPS of -$0.79, missing estimates by -103.82%, and revenue of $0.00, 0% as expectations.
How did the market react to GT Biopharma Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -25.34%, changed from $0.92 before the earnings release to $0.69 the day after.
When is GT Biopharma Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 19, 2026.
What are the forecasts for GT Biopharma Inc. Common Stock's next earnings report?
Based on 3
analysts, GT Biopharma Inc. Common Stock is expected to report EPS of -$0.22 and revenue of -- for Q4 2025.